TBPH

13.99

3.58% -0.52

Handel nachbörslich: 13.99

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$14.51

Offen:

$14.44

24-Stunden-Volumen:

236.60K

Relative Volume:

0.64

Marktkapitalisierung:

$704.55M

Einnahmen:

$62.02M

Nettoeinkommen (Verlust:

$-45.65M

KGV:

-15.21

EPS:

-0.92

Netto-Cashflow:

$-9.60M

1W Leistung:

-2.91%

1M Leistung:

+2.57%

6M Leistung:

+66.75%

1J Leistung:

+73.57%

1-Tages-Spanne:

$13.85

$14.44

1-Wochen-Bereich:

$13.85

$15.15

52-Wochen-Spanne:

$7.90

$15.15

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1141)

Branche

Biotechnology (637)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	13.99	730.74M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-12	Eingeleitet	B. Riley Securities	Buy
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

Oct 10, 2025

How to integrate Theravance Biopharma Inc. into portfolio analysis toolsJuly 2025 Snapshot & Safe Capital Investment Plans - newser.com

Oct 10, 2025

Will breakout in Theravance Biopharma Inc. lead to full recovery2025 Technical Overview & Risk Controlled Swing Trade Alerts - newser.com

Oct 10, 2025

Theravance Biopharma Hits New 52-Week High of $15.15, Up 67.59% - Markets Mojo

Oct 10, 2025

Relative strength of Theravance Biopharma Inc. in sector analysisEarnings Recap Report & Entry Point Confirmation Alerts - newser.com

Oct 10, 2025

Is Theravance Biopharma Inc. (0TB) stock positioned for secular growthJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com

Oct 10, 2025

Oct 09, 2025

What analysts say about Theravance Biopharma Inc stockInsider Trading Compliance & Build Capital Safely - earlytimes.in

Oct 09, 2025

Theravance Biopharma (NASDAQ:TBPH) Earns “Hold (C)” Rating from Weiss Ratings - Defense World

Oct 09, 2025

Oct 06, 2025

Identifying reversal signals in Theravance Biopharma Inc.Weekly Stock Report & Daily Oversold Bounce Ideas - newser.com

Oct 06, 2025

Published on: 2025-10-06 07:12:34 - newser.com

Oct 06, 2025

Can swing trading help recover from Theravance Biopharma Inc. lossesWeekly Risk Summary & Weekly Watchlist for Hot Stocks - newser.com

Oct 06, 2025

Will Theravance Biopharma Inc. benefit from macro trendsJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com

Oct 06, 2025

Oct 05, 2025

How to manage a losing position in Theravance Biopharma Inc.Watch List & Verified Short-Term Plans - newser.com

Oct 05, 2025

Can Theravance Biopharma Inc. (0TB) stock hit consensus price targetsJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - newser.com

Oct 05, 2025

Can Theravance Biopharma Inc. (0TB) stock double in coming years2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com

Oct 05, 2025

What insider purchases suggest about Theravance Biopharma Inc. (0TB) stockProduct Launch & Weekly High Conviction Ideas - newser.com

Oct 05, 2025

Oct 03, 2025

Published on: 2025-10-03 07:08:04 - newser.com

Oct 03, 2025

Leading vs lagging indicators on Theravance Biopharma Inc. performanceJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com

Oct 03, 2025

What RSI levels show for Theravance Biopharma Inc. (0TB) stock2025 Top Decliners & Risk Controlled Daily Plans - newser.com

Oct 03, 2025

Oct 02, 2025

Theravance Biopharma Inc. stock momentum explainedWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 02, 2025

Voya Investment Management LLC Reduces Stock Holdings in Theravance Biopharma, Inc. $TBPH - Defense World

Oct 02, 2025

Oct 01, 2025